Alzheimer's robs its victims of their memories and there is no cure, but there are things you can do to prevent Alzheimer's ...

Experts are expecting this Memorial Day weekend to be the busiest yet, with nearly 44 million Americans projected to travel ...

And though drugs that have some effect on Alzheimer’s disease, dementia’s most common manifestation, have recently been ...

The FDA has accepted Eisai and Biogen’s biologics license application for a monthly infusion of IV Leqembi to treat ...

CR Pharmaceutical and NAMI collaborate to explore palbociclib’s potential for Alzheimer’s treatment, leveraging ...

Bristol Myers Squibb (NYSE:BMY) believes Alzheimer’s is the largest market for its newly approved schizophrenia drug, Cobenfy, which it expects to eventually generate billions of dollars in revenue.

The OIG recommended that the FDA define factors that would trigger an application's review by an agency council, which the agency disagreed with.

According to a study published in Nature Medicine, about 42% of people over the age of 55 will develop dementia in their ...

Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer’s-related psychosis during the ...

Despite initial slow sales, the firm's CEO cited areas for Leqembi's growth and ambitions for an antisense oligonucleotide ...

The FDC released a second highly critical report of PBMs, which may provide further impetus for legislative action to curb ...

A Bismarck man who had pleaded guilty to a financial crime against an elderly family member suffering from Alzheimer's ...